Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
GlaxoSmithKline
Age
40–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Informed consent written prior to the recruit into the study
Male or female subjects
Patients with diagnosis of essential, uncomplicated hypertension
After one to two weeks washout period, patients showing, systolic blood pressure equal or lager than 160mmHg or diastolic blood pressure equal or lager than 90mmHg
Subject could be enrolled in one of the following state:
1. Patients previously untreated for hypertension;
2. Intolerant or not responding to their current therapy;
3. Patients controlled under their previous therapy but who can safely and agree to be switched to the trial therapy could clinically feasible for mono-therapy for hypertension control.
You may not be if
Any form of secondary hypertension
History of malignant hypertension or evidence of accelerated hypertension
Myocardial infarction within 3 months
Unstable angina pectoris
Congestive heart failure
Atrial fibrillation
Life threatening arrhythmia
History of cerebrovascular accident
Clinically relevant renal disease; defines if serum creatinine equal or lager than 1.5 mg/dl
Liver function abnormal: glutamic-oxalacetic transaminase lager than 2 times of upper limit normal or glutamic-pyruvic transaminase lager than 2 times of upper limit normal
Existence of any serious systemic disease
Allergic history to the compounds of both study medication
Can not comply the study protocol or misunderstand the informed consent form
Other diseases which treated by calcium channel blockers
Clareo Health | The Efficacy And Safety Of Lacidipine And Amlodipine Once-Daily Treatment In Hypertensive Adult Patients
